|
Salehi B, Lopez-Jornet P, Pons-Fuster Lopez E, Calina D, Sharifi-Rad M, Ramirez-Alarcon K, Forman K, Fernandez M, Martorell M, Setzer WN, Martins N, Rodrigues CF, Sharifi-Rad J. Plant-Derived Bioactives in Oral Mucosal Lesions: A Key Emphasis to Curcumin, Lycopene, Chamomile, Aloe vera, Green Tea and Coffee Properties. Biomolecules. 2019 Mar 17;9(3):106. doi: 10.3390/biom9030106. PubMed PMID: 30884918; PubMed Central PMCID: PMC6468600.
AÑO: 2019; IF: 4.082
|
30884918
|
Salmeron D, Gomez Garcia F, Pons-Fuster E, Perez-Sayans M, Lorenzo-Pouso AI, Lopez-Jornet P. Screening for prediabetes and risk of periodontal disease. Diabetes Metab Syndr. 2019 Mar-Apr;13(2):1661-1666. doi: 10.1016/j.dsx.2019.03.006. Epub 2019 Mar 12. PubMed PMID: 31336538.
AÑO: 2019
|
|
Imani MM, Lopez-Jornet P, Pons-Fuster Lopez E, Sadeghi M. Polymorphic Variants of V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog B (rs13041247 and rs11696257) and Risk of Non-Syndromic Cleft Lip/Palate: Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2019 Aug 5;16(15):2792. doi: 10.3390/ijerph16152792. PubMed PMID: 31387249; PubMed Central PMCID: PMC6695977.
AÑO: 2019; IF: 2.849
|
|
Pons-Fuster López E, Seoane Leston J, López Jornet P. Epigallocatechin-3-gallate reduces damage to osteoblast-like cells treated with Zoledronic acid. Arch Oral Biol. 2018 Oct;94:27-32. doi: 10.1016/j.archoralbio.2018.06.018. Epub 2018 Jun 20. PubMed PMID: 29945092.
AÑO: 2018; IF: 1.663
|
|
Pons-Fuster López E, Wang QT, Wei W, López Jornet P. Potential chemotherapeutic effects of diosgenin, zoledronic acid and epigallocatechin-3-gallate on PE/CA-PJ15 oral squamous cancer cell line. Arch Oral Biol. 2017 Oct;82:141-146. doi: 10.1016/j.archoralbio.2017.05.023. Epub 2017 Jun 19. PubMed PMID: 28641180.
AÑO: 2017; IF: 2.05
|